A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)

The purpose of this study is to evaluate if zilovertamab vedotin with standard treatment can help people live longer without the cancer growing or spreading than people who receive standard treatment alone.

Trial Details

NCT ID
NCT06717347
Phase
PHASE3
Sponsor
Merck Sharp & Dohme LLC
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • Zilovertamab vedotin
  • Rituximab
  • Cyclophosphamide
  • Doxorubicin
  • Rituximab Biosimilar
  • Prednisone
Locations (sample)
  • Mobile, Alabama, United States|30.69436,-88.04305
  • Gilbert, Arizona, United States|33.35283,-111.78903
  • Fullerton, California, United States|33.87029,-117.92534
  • Los Alamitos, California, United States|33.80307,-118.07256
  • Golden, Colorado, United States|39.75554,-105.2211

Key Eligibility Criteria

  • Has histologically confirmed diagnosis of diffuse large B-cell lymphoma (DLBCL), by prior biopsy, based on local testing according to the WHO class…
  • Has positron emission tomography (PET) positive disease at screening, defined as 4 to 5 on the Lugano 5-point scale
  • Has received no prior treatment for their DLBCL
  • Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 assessed within 7 days before randomization

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →